KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Treasury Shares (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Treasury Shares for 16 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 15.2% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Dec 2025, up 15.2%, and an annual FY2025 reading of $5.2 million, up 15.2% over the prior year.
  • Treasury Shares was $5.2 million for Q4 2025 at Biomarin Pharmaceutical, up from $4.5 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $5.2 million in Q4 2025 and bottomed at $92410.0 in Q1 2021.
  • Average Treasury Shares over 5 years is $3.0 million, with a median of $4.5 million recorded in 2024.
  • The sharpest move saw Treasury Shares decreased 27.07% in 2021, then soared 1087.47% in 2023.
  • Year by year, Treasury Shares stood at $92410.0 in 2021, then soared by 328.65% to $396120.0 in 2022, then skyrocketed by 1087.47% to $4.7 million in 2023, then fell by 3.55% to $4.5 million in 2024, then increased by 15.2% to $5.2 million in 2025.
  • Business Quant data shows Treasury Shares for BMRN at $5.2 million in Q4 2025, $4.5 million in Q4 2024, and $4.7 million in Q4 2023.